JPRN-jRCT2051220031进行中（未招募）2 期
A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis - PROXYMO-ADVANCE
Ageishi Yuji0 个研究点目标入组 8 人开始时间: 2022年5月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1. Provision of informed consent
- •2. Males and female participants more or 18 to less or equal to 75 years of age (inclusive) at the time of signing the informed consent.
- •3. Histologically confirmed non-alcoholic steatohepatitis (NASH) per NASH Clinical Research Network (CRN) criteria as diagnosed by histology from a liver biopsy performed less than or equal to 180 days from randomization and fulfilling all of the following histological criteria:
- •a. NAS (Non-alcoholic Fatty Liver Disease Activity Score) more or equal to 4 with a score of less or equal to 1 for each component: steatosis, lobular inflammation, and ballooning
- •b. Presence of fibrosis stage F2 or F3
- •4. Women of childbearing potential, non-pregnant and nonbreastfeeding and using appropriate birth control to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of study intervention.
排除标准
- •1. Chronic liver disease of other etiologies.
- •2. History of cirrhosis and/or hepatic decompensation, including evidence of portal hypertension (e.g. low platelet count, splenomegaly, ascites, history of hepatic encephalopathy, esophageal varices, or variceal bleeding).
- •3. Clinically significant cardiovascular or cerebrovascular disease within90 days prior to screening, including but not limited to, myocardial infarction, acute coronary syndrome, unstable angina pectoris, transient ischemic attack, or stroke, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 90 days or who are due to undergo these procedures at the time of screening
- •4. History of malignant neoplasms within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or any in situ carcinoma.
- •5. Participation in another clinical study with an investigational product administered within the last 30 days or 5 half-lives of the therapy (whichever is longer) at the time of screening or the time of the historical biopsy or concurrent participation in another interventional study of any kind or prior randomization in this study.
- •6. Severe allergy/hypersensitivity to any of the proposed study treatments or excipients
- •7. Contraindication to liver biopsy (eg, bleeding diathesis, such as hemophilia, suspected hemangioma, or suspected echinococcal infection) or inability to safely obtain a liver biopsy as determined by the investigator
- •8. Severely uncontrolled hypertension defined as SBP more or equal to 180 mmHg or DBP more or equal to 110 mmHg on the average of 2 seated BP measurements after being at rest for at least 10 minutes at screening or randomization
- •9. Any positive results for human immunodeficiency virus infection, positive results for hepatitis B surface antigen or hepatitis C antibody test along with a positive HCV RNA test.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of cotadutide given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosisEUCTR2021-005484-53-ATAstraZeneca AB55
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of cotadutide given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosison-cirrhotic non-alcoholic steatohepatitis with fibrosisMedDRA version: 24.1Level: LLTClassification code 10086370Term: NASH with fibrosisSystem Organ Class: 100000004871EUCTR2021-005484-53-GRAstraZeneca AB55
进行中（未招募）
1 期
A Clinical Trial to Examine the Effects of the Drug Atacicept in Patients with Nephropathy (Diabetic Kidney Disease).EUCTR2016-002262-31-GBMerck KGaA50
已完成
2 期
A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA NephropathyIgA NephropathyJPRN-jRCT2080223899Merck Biopharma Co., Ltd.60
进行中（未招募）
不适用
A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiotherapy for the treatment of patients with previously untreated unresected late stage III/IV non-metastatic head and neck squamous cell carcinomaEUCTR2004-000358-21-BEAstraZeneca AB224